ReviewCell and tissue research2018
Patient-derived xenografts as preclinical neuroblastoma models.
Review in Cell and tissue research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Three-Dimensional Culture Systems in Neuroblastoma Research.Organoids · 2025Article
- Zebrafish tumour xenograft models: a prognostic approach to epithelial ovarian cancer.NPJ precision oncology · 2024Article
- A biobank of pediatric patient-derived-xenograft models in cancer precision medicine trial MAPPYACTS for relapsed and refractory tumors.Communications biology · 2023Article
- Adaptation of the Th-MYCN Mouse Model of Neuroblastoma for Evaluation of Disseminated Disease.International journal of molecular sciences · 2023Article
- Review
- Analysis of Serial Neuroblastoma PDX Passages in Mice Allows the Identification of New Mediators of Neuroblastoma Aggressiveness.International journal of molecular sciences · 2023Article
- Using 3D-bioprinted models to study pediatric neural crest-derived tumors.International journal of bioprinting · 2023Article
- Article
- Review
- Serine-Threonine Kinase Receptor Associate Protein (STRAP) confers an aggressive phenotype in neuroblastoma via regulation of Focal Adhesion Kinase (FAK).Journal of pediatric surgery · 2022Article
- Correlation between Patient-Derived Xenograft Modeling and Prognosis in Osteosarcoma.Orthopaedic surgery · 2022Article
- Metastatic human hepatoblastoma cells exhibit enhanced tumorigenicity, invasiveness and a stem cell-like phenotype.Journal of pediatric surgery · 2022Article
- Environmental cues from neural crest derivatives act as metastatic triggers in an embryonic neuroblastoma model.Nature communications · 2022Article
- Long noncoding RNA LINC01296 regulates the cell proliferation, migration and invasion in neuroblastoma.Metabolic brain disease · 2022Article
- Targeting High-Risk Neuroblastoma Patient-Derived Xenografts with Oncolytic Virotherapy.Cancers · 2022Article
- Mouse Models of Hepatocellular Carcinoma: Classification, Advancement, and Application.Frontiers in oncology · 2022Review
- Progress of oncolytic virotherapy for neuroblastoma.Frontiers in pediatrics · 2022Review
- Current research developments of patient-derived tumour xenograft models (Review).Experimental and therapeutic medicine · 2021Review
- Anti-GD2 IgA kills tumors by neutrophils without antibody-associated pain in the preclinical treatment of high-risk neuroblastoma.Journal for immunotherapy of cancer · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prognosis for children with high-risk neuroblastoma is often poor and survivors can suffer from severe side effects. Predictive preclinical models and novel therapeutic strategies for high-risk disease are therefore a clinical imperative. However, conventional cancer cell line-derived xenografts can deviate substantially from patient tumors in terms of their molecular and phenotypic features. Patient-derived xenografts (PDXs) recapitulate many biologically and clinically relevant features of human cancers. Importantly, PDXs can closely parallel clinical features and outcome and serve as excellent models for biomarker and preclinical drug development. Here, we review progress in and applications of neuroblastoma PDX models. Neuroblastoma orthotopic PDXs share the molecular characteristics, neuroblastoma markers, invasive properties and tumor stroma of aggressive patient tumors and retain spontaneous metastatic capacity to distant organs including bone marrow. The recent identification of genomic changes in relapsed neuroblastomas opens up opportunities to target treatment-resistant tumors in well-characterized neuroblastoma PDXs. We highlight and discuss the features and various sources of neuroblastoma PDXs, methodological considerations when establishing neuroblastoma PDXs, in vitro 3D models, current limitations of PDX models and their application to preclinical drug testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.